Value-Based Medtech Rides The Money-Go-Round Into 2016
Executive Summary
The wider medtech industry saw only 2% growth in 2015, and medtechs in established markets face continued low growth for the next three to five years. The medtech M&A bonanza continued into 2015 and there is no end in sight in 2016 as manufacturers seek to augment and fine-tune portfolios to meet the new demands of payers and providers; longer term, there are signs of a change in the top global medtech rankings.